Atai life sciences increases loan in principal by us$6m to support intelgenx's graduation to toronto stock exchange after positive early feasibility study data

New york, sept. 15, 2021 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“loan agreement”) with strategic partner intelgenx technologies corp. (“intelgenx”) to support intelgenx's conditionally approved graduation from the tsx venture exchange to the toronto stock exchange (“tsx”). completion of the uplisting and the commencement of trading of intelgenx's common shares, 8% convertible debentures with a maturity date of june 30, 2022, and share purchase warrants expiring on february 11, 2023 is subject to the satisfaction by intelgenx of all of the final conditions of listing.
ATAI Ratings Summary
ATAI Quant Ranking